PL2134353T3 - Dwufazowa kompozycja pęcherzyków lipidowych i sposób leczenia dysplazji szyjki macicy przez podawanie dopochwowe - Google Patents

Dwufazowa kompozycja pęcherzyków lipidowych i sposób leczenia dysplazji szyjki macicy przez podawanie dopochwowe

Info

Publication number
PL2134353T3
PL2134353T3 PL08733666T PL08733666T PL2134353T3 PL 2134353 T3 PL2134353 T3 PL 2134353T3 PL 08733666 T PL08733666 T PL 08733666T PL 08733666 T PL08733666 T PL 08733666T PL 2134353 T3 PL2134353 T3 PL 2134353T3
Authority
PL
Poland
Prior art keywords
cervical dysplasia
treating cervical
vesicle composition
intravaginal delivery
biphasic lipid
Prior art date
Application number
PL08733666T
Other languages
English (en)
Polish (pl)
Inventor
Marianna Foldvari
Praveen Kumar
John M. Docherty
Original Assignee
Helix Biopharma Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biopharma Corp. filed Critical Helix Biopharma Corp.
Publication of PL2134353T3 publication Critical patent/PL2134353T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08733666T 2007-03-30 2008-03-27 Dwufazowa kompozycja pęcherzyków lipidowych i sposób leczenia dysplazji szyjki macicy przez podawanie dopochwowe PL2134353T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90932407P 2007-03-30 2007-03-30

Publications (1)

Publication Number Publication Date
PL2134353T3 true PL2134353T3 (pl) 2017-06-30

Family

ID=39807744

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08733666T PL2134353T3 (pl) 2007-03-30 2008-03-27 Dwufazowa kompozycja pęcherzyków lipidowych i sposób leczenia dysplazji szyjki macicy przez podawanie dopochwowe

Country Status (18)

Country Link
US (3) US8945529B2 (enExample)
EP (1) EP2134353B1 (enExample)
JP (1) JP5587762B2 (enExample)
KR (1) KR20090130081A (enExample)
AU (1) AU2008234364B2 (enExample)
CA (1) CA2681565C (enExample)
CY (1) CY1118794T1 (enExample)
DK (1) DK2134353T3 (enExample)
ES (1) ES2617063T3 (enExample)
HR (1) HRP20170250T1 (enExample)
HU (1) HUE033256T2 (enExample)
LT (1) LT2134353T (enExample)
MX (1) MX2009010405A (enExample)
PL (1) PL2134353T3 (enExample)
PT (1) PT2134353T (enExample)
SI (1) SI2134353T1 (enExample)
TW (1) TWI440477B (enExample)
WO (1) WO2008119160A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008900B1 (fr) * 2013-07-25 2018-03-30 Centre Nat Rech Scient Nanoparticules lipidiques multicompartimentees
US8986732B2 (en) * 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) * 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
EP3625345B1 (en) 2017-05-18 2023-05-24 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
CA3064782A1 (en) * 2017-05-26 2018-11-29 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
CA3079428A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
MX2021003015A (es) 2018-09-13 2021-07-15 Modernatx Inc Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis.
AU2019339430A1 (en) 2018-09-14 2021-04-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome
CN118512401A (zh) * 2019-09-23 2024-08-20 迪迪艾斯研究公司 具有渗透促进剂的脂质囊泡组合物
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
US20240207444A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
BR112023019249A2 (pt) 2021-03-24 2023-12-12 Glo Pharma Inc Peptídeos e métodos para reduzir a pigmentação da pele
US20240207374A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
KR20240102989A (ko) * 2021-11-04 2024-07-03 글로 파마, 인크. 화장품 적용을 위한 방법 및 조성물
TW202412818A (zh) 2022-07-26 2024-04-01 美商現代公司 用於暫時控制表現之經工程化多核苷酸
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
EP0711148B1 (en) * 1993-07-28 2000-08-30 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
IN184589B (enExample) * 1996-10-16 2000-09-09 Alza Corp
US5993852A (en) 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
US6656499B1 (en) * 1999-11-12 2003-12-02 Pharmaderm Laboratories, Ltd. Composition for transdermal and dermal administration of interferon-α
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile

Also Published As

Publication number Publication date
MX2009010405A (es) 2010-02-03
EP2134353A4 (en) 2013-08-07
JP2010522698A (ja) 2010-07-08
JP5587762B2 (ja) 2014-09-10
TWI440477B (zh) 2014-06-11
US20100196453A1 (en) 2010-08-05
PT2134353T (pt) 2017-02-15
HRP20170250T1 (hr) 2017-04-07
SI2134353T1 (sl) 2017-03-31
CA2681565C (en) 2016-10-25
DK2134353T3 (en) 2017-02-20
US20130216610A1 (en) 2013-08-22
CY1118794T1 (el) 2017-07-12
TW200846030A (en) 2008-12-01
EP2134353B1 (en) 2016-11-16
ES2617063T3 (es) 2017-06-15
HUE033256T2 (hu) 2017-11-28
KR20090130081A (ko) 2009-12-17
CA2681565A1 (en) 2008-10-09
LT2134353T (lt) 2017-03-27
US8945529B2 (en) 2015-02-03
EP2134353A1 (en) 2009-12-23
AU2008234364A1 (en) 2008-10-09
WO2008119160A1 (en) 2008-10-09
US20130224283A1 (en) 2013-08-29
AU2008234364B2 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
LT2134353T (lt) Dvifazė lipidų vezikulių kompozicija ir gimdos kaklelio displazijos gydymo būdas, skiriant intravaginaliai
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
IL216668A0 (en) Pharmaceutical composition and treatment method for emergrncy contraception
EP2229171A4 (en) METHOD AND COMPOSITIONS FOR TREATING POST-OPERATIVE PAIN WITH A LOCAL ANESTHETIC
AP3438A (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
IL205196A0 (en) Implant delivery device and method
EP2473196A4 (en) ADMINISTRATION OF SDF-1 FOR THE TREATMENT OF ISCHEMIC FABRICS
ZA201006293B (en) Composition and method for seed treatment use
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
PL2349231T3 (pl) Kompozycje i metody leczenia chorób kopyta
IL198723A0 (en) Methods and compositions for therapeutic treatment
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
IL206173A0 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
ZA201103626B (en) Intravaginal delivery system and process for manufacturing it
EP2043662A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASE
EP2329819A4 (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF SEXUALLY TRANSMITTED INFECTIONS
IL209947A0 (en) Compositions and methods for treating corneal inflammation
EP2517704A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND METHOD OF MAKING SAME
PL2134742T3 (pl) Kompozycje immunogenne do leczenia i profilaktyki zakażeń zwierząt
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
ZA200807049B (en) Compositions and methods for treating collagen-mediated diseases